PD-1 anticorps

N° du produit ABIN2665970

L’anticorps Souris Monoclonal anti-PD-1 a été validé pour FACS, WB et IHC. Il convient pour détecter PD-1 dans des échantillons de Humain.

Aperçu rapide pour PD-1 anticorps (ABIN2665970)

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp PD-1 est non-conjugé

Application: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)

Clone: EH12-2H7

Détail du produit anti-PD-1 anticorps

Marque: Ultra-LEAF™

Réactivité croisée: Chimpanzé, Marmoset, Macaque rhésus, Squirrel Monkey (Saimiri spec.), Cynomolgus

Purification: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

Stérilité: 0.2 μm filtered

niveau d'endotoxine:

Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Agent conservateur: Azide free

Conseil sur la manipulation: This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur PD-1

Antigène: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Autre désignation: CD279

Sujet: Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Pathways: Cancer Immune Checkpoints